Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders.

Lopez-Pedrera C, Barbarroja N, Patiño-Trives AM, Luque-Tévar M, Torres-Granados C, Aguirre-Zamorano MA, Collantes-Estevez E, Pérez-Sánchez C.

Int J Mol Sci. 2020 Mar 16;21(6). pii: E2012. doi: 10.3390/ijms21062012. Review.

2.

Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies.

Arias de la Rosa I, Perez-Sanchez C, Ruiz-Limon P, Patiño-Trives A, Torres-Granados C, Jimenez-Gomez Y, Abalos-Aguilera MDC, Cecchi I, Ortega R, Caracuel MA, Calvo-Gutierrez J, Escudero-Contreras A, Collantes-Estevez E, Lopez-Pedrera C, Barbarroja N.

Haematologica. 2020 Jan 16. pii: haematol.2018.205047. doi: 10.3324/haematol.2018.205047. [Epub ahead of print]

3.

Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis.

Barbarroja N, Arias-de la Rosa I, López-Medina C, Camacho-Sánchez MDR, Gómez-García I, Vélez-García AJ, Escudero-Contreras A, López-Pedrera C, López-Montilla MD, Collantes-Estévez E.

Ther Adv Musculoskelet Dis. 2019 Oct 16;11:1759720X19880742. doi: 10.1177/1759720X19880742. eCollection 2019. No abstract available.

4.

Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion.

Pérez-Sánchez C, Cecchi I, Barbarroja N, Patiño-Trives AM, Luque-Tévar M, Pérez-Sánchez L, Ibáñez-Costa A, Arias de la Rosa I, Ortega R, Escudero A, Castro MC, Radin M, Roccatello D, Sciascia S, Aguirre MÁ, Collantes E, López-Pedrera C; BIOSAR Study Group.

J Cell Mol Med. 2019 Sep;23(9):6308-6318. doi: 10.1111/jcmm.14517. Epub 2019 Jul 26.

5.

Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis.

Ruiz-Limon P, Ortega-Castro R, Barbarroja N, Perez-Sanchez C, Jamin C, Patiño-Trives AM, Luque-Tevar M, Ibáñez-Costa A, Perez-Sanchez L, de la Rosa IA, Abalos-Aguilera M, Jimenez-Gomez Y, Calvo-Gutierrez J, Font P, Escudero-Contreras A, Alarcon-Riquelme ME, Collantes-Estevez E, López-Pedrera C; PRECISESADS Clinical Consortium and Flow Cytometry Study Group.

Front Immunol. 2019 May 21;10:1111. doi: 10.3389/fimmu.2019.01111. eCollection 2019.

6.

New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches.

Lopez-Pedrera C, Barbarroja N, Patiño-Trives AM, Collantes E, Aguirre MA, Perez-Sanchez C.

Front Immunol. 2019 Apr 16;10:764. doi: 10.3389/fimmu.2019.00764. eCollection 2019. Review.

7.

Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS.

Arias de la Rosa I, Radin M, Cecchi I, Rubini E, Pérez-Sánchez C, Aguirre MÁ, Menegatti E, Barbarroja N, Collantes E, Sciascia S, Roccatello D, López Pedrera C.

Rheumatology (Oxford). 2019 Oct 1;58(10):1870-1872. doi: 10.1093/rheumatology/kez166. No abstract available.

PMID:
31034051
8.

Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets.

Cecchi I, Arias de la Rosa I, Menegatti E, Roccatello D, Collantes-Estevez E, Lopez-Pedrera C, Barbarroja N.

Autoimmun Rev. 2018 Nov;17(11):1138-1149. doi: 10.1016/j.autrev.2018.06.006. Epub 2018 Sep 11. Review.

PMID:
30217550
9.

Are monkeys intuitive Aristotelians? Associations between target size and vertical target position in long-tailed macaques.

Keupp S, Barbarroja N, Topolinski S, Fischer J.

R Soc Open Sci. 2018 Apr 11;5(4):170889. doi: 10.1098/rsos.170889. eCollection 2018 Apr.

10.

Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome.

Pérez-Sánchez C, Arias-de la Rosa I, Aguirre MÁ, Luque-Tévar M, Ruiz-Limón P, Barbarroja N, Jiménez-Gómez Y, Ábalos-Aguilera MC, Collantes-Estévez E, Segui P, Velasco F, Herranz MT, Lozano-Herrero J, Hernandez-Vidal MJ, Martínez C, González-Conejero R, Radin M, Sciascia S, Cecchi I, Cuadrado MJ, López-Pedrera C.

Haematologica. 2018 May;103(5):908-918. doi: 10.3324/haematol.2017.184416. Epub 2018 Mar 15.

11.

Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues.

Arias de la Rosa I, Escudero-Contreras A, Rodríguez-Cuenca S, Ruiz-Ponce M, Jiménez-Gómez Y, Ruiz-Limón P, Pérez-Sánchez C, Ábalos-Aguilera MC, Cecchi I, Ortega R, Calvo J, Guzmán-Ruiz R, Malagón MM, Collantes-Estevez E, Vidal-Puig A, López-Pedrera C, Barbarroja N.

J Intern Med. 2018 Jul;284(1):61-77. doi: 10.1111/joim.12743. Epub 2018 Mar 12.

PMID:
29532531
12.

Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients.

Perez-Sanchez C, Font-Ugalde P, Ruiz-Limon P, Lopez-Pedrera C, Castro-Villegas MC, Abalos-Aguilera MC, Barbarroja N, Arias-de la Rosa I, Lopez-Montilla MD, Escudero-Contreras A, Lopez-Medina C, Collantes-Estevez E, Jimenez-Gomez Y.

Hum Mol Genet. 2018 Mar 1;27(5):875-890. doi: 10.1093/hmg/ddy008.

PMID:
29329380
13.

Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial.

Pérez-Sánchez C, Aguirre MÁ, Ruiz-Limón P, Ábalos-Aguilera MC, Jiménez-Gómez Y, Arias-de la Rosa I, Rodriguez-Ariza A, Fernández-Del Río L, González-Reyes JA, Segui P, Collantes-Estévez E, Barbarroja N, Velasco F, Sciascia S, Cecchi I, Cuadrado MJ, Villalba JM, López-Pedrera C.

Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1923-1932. doi: 10.1161/ATVBAHA.117.309225. Epub 2017 Jul 6.

PMID:
28684614
14.

Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients.

Pérez-Sánchez C, Ruiz-Limón P, Aguirre MA, Jiménez-Gómez Y, Arias-de la Rosa I, Ábalos-Aguilera MC, Rodriguez-Ariza A, Castro-Villegas MC, Ortega-Castro R, Segui P, Martinez C, Gonzalez-Conejero R, Rodríguez-López S, Gonzalez-Reyes JA, Villalba JM, Collantes-Estévez E, Escudero A, Barbarroja N, López-Pedrera C.

J Autoimmun. 2017 Aug;82:31-40. doi: 10.1016/j.jaut.2017.04.007. Epub 2017 Apr 29.

PMID:
28465139
15.

Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation.

Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MDC, Perez-Sanchez C, Jimenez-Gomez Y, Peralbo-Santaella E, Font P, Ruiz-Vilches D, Ferrin G, Collantes-Estevez E, Escudero-Contreras A, López-Pedrera C, Barbarroja N.

Transl Res. 2017 May;183:87-103. doi: 10.1016/j.trsl.2016.12.003. Epub 2016 Dec 9.

PMID:
28027930
16.

Multi-center harmonization of flow cytometers in the context of the European "PRECISESADS" project.

Jamin C, Le Lann L, Alvarez-Errico D, Barbarroja N, Cantaert T, Ducreux J, Dufour AM, Gerl V, Kniesch K, Neves E, Trombetta E, Alarcón-Riquelme M, Marañon C, Pers JO.

Autoimmun Rev. 2016 Nov;15(11):1038-1045. doi: 10.1016/j.autrev.2016.07.034. Epub 2016 Aug 1.

PMID:
27490203
17.

'Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients'.

Pérez-Sánchez C, Aguirre MA, Ruiz-Limón P, Barbarroja N, Jiménez-Gómez Y, de la Rosa IA, Rodriguez-Ariza A, Collantes-Estévez E, Segui P, Velasco F, Cuadrado MJ, Teruel R, González-Conejero R, Martínez C, López-Pedrera Ch.

Sci Rep. 2016 Aug 9;6:31375. doi: 10.1038/srep31375.

18.

Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches.

López-Pedrera C, Barbarroja N, Jimenez-Gomez Y, Collantes-Estevez E, Aguirre MA, Cuadrado MJ.

Rheumatology (Oxford). 2016 Dec;55(12):2096-2108. Epub 2016 Mar 27. Review.

PMID:
27018059
19.

Immunotherapy in antiphospholipid syndrome.

Lopez-Pedrera Ch, Aguirre MA, Ruiz-Limon P, Pérez-Sánchez C, Jimenez-Gomez Y, Barbarroja N, Cuadrado MJ.

Int Immunopharmacol. 2015 Aug;27(2):200-8. doi: 10.1016/j.intimp.2015.06.006. Epub 2015 Jun 15. Review.

PMID:
26086363
20.

Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.

Castro-Villegas C, Pérez-Sánchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limón P, Aguirre MA, Jiménez-Gomez Y, Font P, Rodriguez-Ariza A, Peinado JR, Collantes-Estévez E, González-Conejero R, Martinez C, Barbarroja N, López-Pedrera C.

Arthritis Res Ther. 2015 Mar 9;17:49. doi: 10.1186/s13075-015-0555-z.

21.

Increased dihydroceramide/ceramide ratio mediated by defective expression of degs1 impairs adipocyte differentiation and function.

Barbarroja N, Rodriguez-Cuenca S, Nygren H, Camargo A, Pirraco A, Relat J, Cuadrado I, Pellegrinelli V, Medina-Gomez G, Lopez-Pedrera C, Tinahones FJ, Symons JD, Summers SA, Oresic M, Vidal-Puig A.

Diabetes. 2015 Apr;64(4):1180-92. doi: 10.2337/db14-0359. Epub 2014 Oct 28.

22.

Dihydroceramide desaturase 1, the gatekeeper of ceramide induced lipotoxicity.

Rodriguez-Cuenca S, Barbarroja N, Vidal-Puig A.

Biochim Biophys Acta. 2015 Jan;1851(1):40-50. doi: 10.1016/j.bbalip.2014.09.021. Epub 2014 Oct 2. Review.

PMID:
25283058
23.

Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis.

Barbarroja N, Pérez-Sanchez C, Ruiz-Limon P, Castro-Villegas C, Aguirre MA, Carretero R, Segui P, Jimenez-Gomez Y, Sanna M, Rodriguez-Ariza A, Collantes-Estevez E, Escudero A, López-Pedrera C.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2706-16. doi: 10.1161/ATVBAHA.114.304475. Epub 2014 Sep 25.

PMID:
25256232
24.

Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment.

Ruiz-Limon P, Barbarroja N, Perez-Sanchez C, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Almadén Y, Segui P, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Collantes-Estevez E, Cuadrado MJ, Lopez-Pedrera C.

Ann Rheum Dis. 2015 Jul;74(7):1450-8. doi: 10.1136/annrheumdis-2013-204351. Epub 2014 Mar 21.

PMID:
24658835
25.

Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus.

Perez-Sanchez C, Barbarroja N, Messineo S, Ruiz-Limon P, Rodriguez-Ariza A, Jimenez-Gomez Y, Khamashta MA, Collantes-Estevez E, Cuadrado MJ, Aguirre MA, Lopez-Pedrera C.

Ann Rheum Dis. 2015 Jul;74(7):1441-9. doi: 10.1136/annrheumdis-2013-204600. Epub 2014 Mar 11.

PMID:
24618261
26.

Adaptive changes of the Insig1/SREBP1/SCD1 set point help adipose tissue to cope with increased storage demands of obesity.

Carobbio S, Hagen RM, Lelliott CJ, Slawik M, Medina-Gomez G, Tan CY, Sicard A, Atherton HJ, Barbarroja N, Bjursell M, Bohlooly-Y M, Virtue S, Tuthill A, Lefai E, Laville M, Wu T, Considine RV, Vidal H, Langin D, Oresic M, Tinahones FJ, Fernandez-Real JM, Griffin JL, Sethi JK, López M, Vidal-Puig A.

Diabetes. 2013 Nov;62(11):3697-708. doi: 10.2337/db12-1748. Epub 2013 Aug 6.

27.

Caspase induction and BCL2 inhibition in human adipose tissue: a potential relationship with insulin signaling alteration.

Tinahones FJ, Coín Aragüez L, Murri M, Oliva Olivera W, Mayas Torres MD, Barbarroja N, Gomez Huelgas R, Malagón MM, El Bekay R.

Diabetes Care. 2013 Mar;36(3):513-21. doi: 10.2337/dc12-0194. Epub 2012 Nov 27.

28.

Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation.

Barbarroja N, Lopez-Pedrera C, Garrido-Sanchez L, Mayas MD, Oliva-Olivera W, Bernal-Lopez MR, El Bekay R, Tinahones FJ.

PLoS One. 2012;7(10):e48155. doi: 10.1371/journal.pone.0048155. Epub 2012 Oct 24.

29.

Ablation of PGC1 beta prevents mTOR dependent endoplasmic reticulum stress response.

Camacho A, Rodriguez-Cuenca S, Blount M, Prieur X, Barbarroja N, Fuller M, Hardingham GE, Vidal-Puig A.

Exp Neurol. 2012 Oct;237(2):396-406. doi: 10.1016/j.expneurol.2012.06.031. Epub 2012 Jul 6. Erratum in: Exp Neurol. 2013 Jan;239:101.

30.

Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment.

Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Segui P, Collantes-Estevez E, Barbarroja N, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Velasco F, Cuadrado MJ, Lopez-Pedrera C.

Blood. 2012 Jun 14;119(24):5859-70. doi: 10.1182/blood-2011-12-400986. Epub 2012 Apr 23.

PMID:
22529290
31.

Peroxisome proliferator-activated receptor γ-dependent regulation of lipolytic nodes and metabolic flexibility.

Rodriguez-Cuenca S, Carobbio S, Velagapudi VR, Barbarroja N, Moreno-Navarrete JM, Tinahones FJ, Fernandez-Real JM, Orešic M, Vidal-Puig A.

Mol Cell Biol. 2012 Apr;32(8):1555-65. doi: 10.1128/MCB.06154-11. Epub 2012 Feb 6.

32.

To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer.

Lopez-Pedrera C, Ruiz-Limon P, Valverde-Estepa A, Barbarroja N, Rodriguez-Ariza A.

Curr Drug Targets. 2012 Jun;13(6):829-41. Review.

PMID:
22250652
33.

Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice.

Prieur X, Mok CY, Velagapudi VR, Núñez V, Fuentes L, Montaner D, Ishikawa K, Camacho A, Barbarroja N, O'Rahilly S, Sethi JK, Dopazo J, Orešič M, Ricote M, Vidal-Puig A.

Diabetes. 2011 Mar;60(3):797-809. doi: 10.2337/db10-0705. Epub 2011 Jan 24.

34.

Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome.

López-Pedrera C, Ruiz-Limón P, Aguirre MÁ, Barbarroja N, Pérez-Sánchez C, Buendía P, Rodriguez-García IC, Rodriguez-Ariza A, Collantes-Estevez E, Velasco F, Khasmahta M, Cuadrado MJ.

Ann Rheum Dis. 2011 Apr;70(4):675-82. doi: 10.1136/ard.2010.135525. Epub 2010 Dec 20.

PMID:
21173016
35.

VEGF targeted therapy in acute myeloid leukemia.

Rodriguez-Ariza A, Lopez-Pedrera C, Aranda E, Barbarroja N.

Crit Rev Oncol Hematol. 2011 Nov;80(2):241-56. doi: 10.1016/j.critrevonc.2010.09.009. Epub 2010 Oct 29. Review.

PMID:
21035354
36.

Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.

López-Pedrera C, Aguirre MÁ, Barbarroja N, Cuadrado MJ.

J Biomed Biotechnol. 2010;2010. pii: 607084. doi: 10.1155/2010/607084. Epub 2010 Sep 26. Review.

37.

The obese healthy paradox: is inflammation the answer?

Barbarroja N, López-Pedrera R, Mayas MD, García-Fuentes E, Garrido-Sánchez L, Macías-González M, El Bekay R, Vidal-Puig A, Tinahones FJ.

Biochem J. 2010 Aug 15;430(1):141-9. doi: 10.1042/BJ20100285.

PMID:
20522023
38.

ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK.

González-Aragón D, Alcaín FJ, Ariza J, Jódar L, Barbarroja N, López-Pedrera C, Villalba JM.

Chem Biol Interact. 2010 Jul 30;186(2):174-83. doi: 10.1016/j.cbi.2010.04.022. Epub 2010 Apr 28.

PMID:
20433816
39.

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.

Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.

Exp Hematol. 2010 Aug;38(8):641-52. doi: 10.1016/j.exphem.2010.03.017. Epub 2010 Apr 7.

PMID:
20380868
40.

Proteomics in antiphospholipid syndrome: a review.

Cuadrado MJ, Aguirre MA, Barbarroja N, Khamashta MA, Lopez-Pedrera Ch.

Lupus. 2010 Apr;19(4):385-8. doi: 10.1177/0961203309360986. Review.

PMID:
20353974
41.

Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome.

López-Pedrera C, Aguirre MA, Buendía P, Barbarroja N, Ruiz-Limón P, Collantes-Estevez E, Velasco F, Khamashta M, Cuadrado MJ.

Arthritis Rheum. 2010 Mar;62(3):869-77. doi: 10.1002/art.27299.

42.

Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.

Barbarroja N, Torres LA, Luque MJ, Carretero RM, Valverde-Estepa A, Lopez-Sanchez LM, Rodriguez-Ariza A, Velasco F, Torres A, López-Pedrera C.

Exp Hematol. 2009 Jun;37(6):679-91. doi: 10.1016/j.exphem.2009.03.001.

PMID:
19463770
43.

VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3-internal tandem duplications.

Torres LA, Barbarroja N, Dorado G, Velasco F, López-Pedrera C.

Br J Haematol. 2009 Jun;145(6):836-8. doi: 10.1111/j.1365-2141.2009.07673.x. Epub 2009 Apr 8. No abstract available.

PMID:
19388942
44.

Novel biomarkers of atherosclerosis and cardiovascular risk in autoimmune diseases: Genomics and proteomics approaches.

López-Pedrera C, Barbarroja N, Villalba JM.

Proteomics Clin Appl. 2009 Feb;3(2):213-25. doi: 10.1002/prca.200800147.

PMID:
26238620
45.

Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases.

López-Pedrera C, Barbarroja N, Aguirre MA, Torres LA, Velasco F, Cuadrado MJ.

Lupus. 2008 Oct;17(10):904-15. doi: 10.1177/0961203308095285. Review.

PMID:
18827055
46.

Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis.

López-Pedrera C, Cuadrado MJ, Herández V, Buendïa P, Aguirre MA, Barbarroja N, Torres LA, Villalba JM, Velasco F, Khamashta M.

Arthritis Rheum. 2008 Sep;58(9):2835-44. doi: 10.1002/art.23756.

47.

[Intracellular mechanisms involved in the angiogenic process in hematological malignancies].

Barbarroja N, Velasco F, López-Pedrera C.

Med Clin (Barc). 2008 Apr 26;130(15):585-90. Review. Spanish.

PMID:
18462638
48.

MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.

Barbarroja N, Siendones E, Torres LA, Luque MJ, Martinez JM, Dorado G, Velasco F, Torres A, López-Pedrera C.

Br J Haematol. 2008 Jul;142(1):27-35. doi: 10.1111/j.1365-2141.2008.07154.x. Epub 2008 Apr 28.

PMID:
18445086
49.

Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia.

Barbarroja N, Arístides-Torres L, Hernandez V, Martín C, Dorado G, Torres A, Velasco F, Lopez-Pedrera C.

Leuk Lymphoma. 2007 Jun;48(6):1187-99.

PMID:
17577783
50.

Supplemental Content

Loading ...
Support Center